Alumis Inc

NASDAQ:ALMSUnited States

Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.

Contact Information

Headquarters

280 East Grand AvenueSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-231-6625

Fax

302-531-3150

Executives

Chairman of the Board, President, Chief Executive Officer

Martin Babler

Chief Financial Officer

John Schroer

Senior Vice President - People and Culture

Derrick Richardson

Chief Scientific Officer

David Goldstein

General Counsel, Corporate Secretary

Sara Klein